With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

Debra (“Debbie”) Neis Rogers, nee Kelly, was born September 20, 1956, in Parkersburg, WV. She passed away unexpectedly on January 14, 2025. A beloved wife, mother, sister, friend, and community leader ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Her work previously appeared in Newsweek. NBCUniversal via Getty Debbie Allen has been an icon of the stage and screen for more than four decades! The multi-hyphenate, who turns 75 on Jan. 16 ...

Jan. 16 (UPI) --Those born on this date are under the sign of Capricorn. They include: Advertisement -- Industrialist Andre Michelin in 1853 -- Poet Robert Service in 1874 -- Inventor Frank ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

Seattle Mariners second base Jorge Polanco (7) hits against the Oakland Athletics in the sixth inning at Oakland-Alameda County Coliseum in 2024. / Eakin Howard-Imagn Images We've heard throughout ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...

Regeneron’s total addressable commercial market is expected to exceed $220 billion by 2030. Some near-term highlights include: ...